The primary objective of this phase 1 trial is to determine the dose-dependent toxicity and
maximum tolerated dose (MTD) of oncolytic adenovirus-mediated cytotoxic gene therapy in
combination with SBRT in medically inoperable stage I/IIA (T1A - T2B) NSCLC. To accomplish
this objective, 9 subjects will be enrolled in the study. We hypothesize that the combined
treatment will demonstrate acceptable toxicity, and that it will be feasible to quantify
adenovirus-mediated HSV-1 TK gene expression in the lung by PET. This phase 1 trial will lay
the foundation for a follow-up phase 2 trial designed to examine efficacy.